Acceleron Careers


At Acceleron, we are dedicated to bringing innovative, life-changing therapies to patients with a wide range of serious and rare diseases. Our scientific leadership and broad platform have enabled us to produce a rich pipeline of important new medicines for rare blood disorders and pulmonary diseases.

  • Luspatercept-aamt is a first-in-class erythroid (red blood cell) maturation agent being developed to treat patients who have serious blood disorders associated with ineffective erythropoiesis. Discovered by scientists at Acceleron, luspatercept-aamt is a recombinant fusion protein that binds several TGF-beta superfamily ligands, thereby diminishing Smad2/3 signaling. The U.S. Food and Drug Administration has approved REBLOZYL┬« (luspatercept-aamt) for the treatment of anemia in adult patients with beta-thalassemia who require regular red blood cell (RBC) transfusions and for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell (RBC) units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).
  • In our pulmonary program, we are developing sotatercept for the treatment of pulmonary arterial hypertension, having recently reported positive topline results of the Phase 2 PULSAR trial and actively enrolling patients in the Phase 2 SPECTRA trial.

The clinical trials listed below are Acceleron or partner-sponsored trials, some of which are actively recruiting patients. Each trial in the list contains a link to, where you will find a full description and contact information.

Clinical Trial Transparency: Acceleron is committed to public health and scientific exchange. As a part of this commitment, we make our clinical trial information accessible so that patients, health care providers, and the general public are included in the conversation. Click here to learn more about Acceleron’s Policy on Clinical Trial Transparency.

Drug Study Phase Disease
Luspatercept COMMANDS Phase III* Low or Intermediate Risk MDS
Luspatercept BEYOND Phase II* Beta-Thalassemia
Luspatercept Phase II* Myelofibrosis
Luspatercept Phase II Extension MDS
Luspatercept Phase II Extension Beta-Thalassemia
Luspatercept Phase II Anemia in Lower-Risk MDS
Luspatercept Phase II Beta-Thalassemia
Sotatercept PULSAR Phase II Pulmonary Arterial Hypertension
Sotatercept SPECTRA Phase II Pulmonary Arterial Hypertension
Acceleron trials listed as recruiting or active on

* Bristol-Myers Squibb-sponsored